Alkermes plc
Every calculator, already run for ALKS
Open the full toolkit →You have the numbers on ALKS. Get the argument.
A written report on which of these readings actually decide the outcome for Alkermes plc, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
19 analysts covering ALKSAnalyst Price Target Disagreement for Alkermes plc
Wall Street's bull case implies +107% from the current price; the bear case implies -5%. A 112% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ALKS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatm…
ALKS — frequently asked
Is ALKS a buy right now?
Wall Street's consensus rating on Alkermes plc is Buy across 19 analysts, with a mean price target of $56.56 (+41% vs. the current $40.15). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ALKS overvalued?
ALKS trades at 108.5x trailing earnings, against a DCF fair value of $36 per share. The current price implies 7% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ALKS's next earnings date?
Alkermes plc is next scheduled to report earnings around Oct 28, 2026. A full ALKS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Alkermes plc?
Analysts covering Alkermes plc (ALKS) range from a bear-case target of $38.00 to a bull-case high of $83.00, with a mean consensus target of $56.56 across 18 analysts. The spread of $45.00 (112% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Alkermes plc against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Alkermes plc
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ALKS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Alkermes plc, in minutes. 3 free reports included with every account — no credit card required.